Evaluation of the Clinical Performance of 7 Serological Assays for SARS-CoV-2 for Use in Clinical Laboratories

6Citations
Citations of this article
32Readers
Mendeley users who have this article in their library.

Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serological assays have emerged as a response to the global pandemic, warranting studies evaluating their clinical performance. This study investigated 7 commercially available SARS-CoV-2 serological assays in samples from noninfected individuals and hospitalized patients. Methods: SARS-CoV-2 qualitative serological assays by Abbott (IgG), Beckman (IgG), DiaSorin (IgG), EUROIMMUN (IgG and IgA), Roche and Bio-Rad (Total) were evaluated using specimens collected pre-December 2019 (n ¼ 393), from nucleic acid amplification testing (NAAT) negative patients (n ¼ 40), and from 53 patients with COVID-19 by NAAT collected 3–21 days post-onset of symptoms (POS) (N ¼ 83). Negative agreement (NA), positive agreement (PA), and positive and negative predictive values (PPV and NPV) at prevalences of 5% and 10% were calculated. Results: The overall %NA; 95% CI in the negative samples were: Roche 99.8%; 99.3–100.2, Beckman 99.8%; 98.7– 100.0, Abbott and Bio-Rad 99.3%; 98.0–99.9, DiaSorin 98.4; 97.2–99.6, EUROIMMUN IgG 97.5%; 95.5–98.7, and EUROIMMUN IgA 79.7%; 75.9–83.5), accounting for positive/equivocal results as false positives. The %PA; 95% CI in samples collected 14þ days POS (n ¼ 24) were: Bio-Rad 83.3%; 68.4–98.2, Abbott and Roche 79.2%; 62.9–95.4, EUROIMMUN IgA 70.8%; 52.6–89.0, Beckman 58.3%; 38.6–78.1, DiaSorin 54.2; 34.2–74.1, and EUROIMMUN IgG 50.0%; 30.0–70.0, accounting for negative/equivocal results as false negatives. NPVs ranged from 97.4%–98.9% and 94.7%–97.7% for prevalences 5% and 10%, respectively. PPVs ranged from 15.5%–94.8% and 27.9%–97.4% for prevalences 5% and 10%, respectively. Conclusion: The Roche and Beckman assays resulted in fewer false positives, followed by the Bio-Rad and Abbott assays. While the Bio-Rad assay demonstrated higher antibody detection in COVID-19-positive patients, PA claims cannot be established with a high level of confidence in our sample population.

Author supplied keywords

Cite

CITATION STYLE

APA

Plaga, A., Wei, R., Olson, E., Payto, D., Harrington, J., Nwe-Kissig, P. T., … Colón-Franco, J. M. (2021). Evaluation of the Clinical Performance of 7 Serological Assays for SARS-CoV-2 for Use in Clinical Laboratories. Journal of Applied Laboratory Medicine, 6(4), 998–1004. https://doi.org/10.1093/jalm/jfab038

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free